Meropenem Aptapharma

Meropenem, the active ingredient in Meropenem Aptapharma, is a carbapenem antibiotic presented as an injection for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired pneumonia, ventilator‑associated pneumonia, and severe sepsis in hospitalized patients.

GNH USA supplies Meropenem Aptapharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies, clinics and other healthcare facilities worldwide.

Meropenem is a carbapenem antibiotic used to treat serious bacterial infections affecting various organ systems.

Complicated intra‑abdominal infections: provides rapid bactericidal activity to resolve infection and reduce mortality. Complicated urinary tract infections: eradicates resistant Gram‑negative pathogens causing severe urinary infections. Hospital‑acquired pneumonia: achieves high lung tissue concentrations to treat resistant pneumonia. Ventilator‑associated pneumonia: offers broad‑spectrum coverage for ventilated patients. Severe sepsis and septic shock: delivers prompt bacterial clearance to support hemodynamic recovery.

Meropenem may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting - Diarrhea, including mild Clostridioides difficile‑associated colitis - Rash or pruritus - Headache - Elevated liver enzymes (ALT, AST) - Injection‑site pain or phlebitis

Serious or Rare Side Effects: - Seizures, especially in patients with renal impairment or CNS disorders - Severe Clostridioides difficile colitis - Anaphylactic or anaphylactoid reactions - Neutropenia or agranulocytosis - Acute renal failure or worsening renal function - Hypersensitivity reactions such as Stevens‑Johnson syndrome

When using Meropenem, clinicians should consider several safety measures. - Renal function: adjust dose in patients with impaired renal function to avoid accumulation. - Allergy: avoid in individuals with known hypersensitivity to carbapenems or other beta‑lactams. - Seizure risk: monitor patients with a history of seizures or central nervous system disorders. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Concomitant valproic acid: monitor for reduced valproate levels and possible seizure breakthrough. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Valproic acid: meropenem reduces serum valproate concentrations, increasing seizure risk. - Phenobarbital: concurrent use may heighten neurotoxic effects.

Moderate Interactions (Monitor Closely): - Loop diuretics: monitor renal function and electrolytes. - Aminoglycosides: watch for additive nephrotoxicity. - Warfarin: observe INR values for possible anticoagulation changes.